Authors: 
J.A.C. Archer
Category: 
Invited
Conference: 
Abstract: 

Degenerative metabolic markers such as lipofuscin or atheroma may be considered as classes of 'dead-end' substrates within the limited mammalian metabolism. However, some microbial enzyme pathways are very much more diverse and in some cases may be able to convert such substrates into metabolically useful products. Recent genomic studies and cell assays indicate that mycolic acid bacteria from the genus Rhodococcus can metabolise such compounds. This presents an opportunity to engineer cellular or cell-free systems that can are highly efficient in recycling lipofuschin or catabolising key recalcitrant components of atherosclerotic plaques.

Keywords (Optional): 
lipofuscin
atherosclerosis
Rhodococcus
catabolism